EN DE
Watch Cronos Group Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cronos Group Inc (CRON) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Cronos Group Inc stock $2.16, price $3.61, that is 40.2% below the price, quality 59 out of 100. Rating: strongly overvalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Canada · ISIN CA22717L1013

CG Cronos Group Inc logo Some data Nov 6, 2026

Cronos Group Inc

CRON · US
Solid, but very expensive

Our calculation puts a fair price 40% below what the stock costs today.

Highly profitable · 39.1% net margin (TTM)
Low debt
Generates free cash flow
Last quarter vs. a year ago: revenue +58%, profit +127%.
Quality 59/100
Mixed Growth (revenue 5y +26.1 %/yr in USD)
Mixed vs. peers (7/12)
Some data
Fair value $2.16 · Strongly overvalued (−40.2%)
Narrow moat 44/100 · thin data
Watch Cronos Group Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$7.31 $1.62 Fair Value $2.16 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $1.62 – $7.31 · fair‑value band $2.15 – $2.16 · the $3.61 price screens above the $2.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.

Follow Cronos Group in your weekly email

Every Wednesday you see whether Cronos Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally.

Show moreShow less

It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.

Stock analysis

Cronos Group Inc (CRON) currently trades at $3.61, while our model-based Fair Value estimate is $2.16, 40% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of $2.28 per share, and 0 of the 6 models we run sit above the $3.61 price.

Bear case: the Multiples group reads lowest at $2.15, and 6 of the 6 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $2.15 (bear) to $2.16 (bull), the price of $3.61 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Cronos Group Inc reported revenue of $149M in FY2025 versus $64.6M in FY2021, a compound +23.3%/yr. Reported net income was −$9.6M in FY2025.

Key figures

Market cap $1.4B Small · P/E ratio 19.0 · P/S ratio 7.77 · EPS (TTM) $0.1900 · Net margin 39.1% · Return on equity 7.1% · Return on assets (EBIT) −9.1% (5-year average) · Operating margin 15.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).

What moves the price

The share trades about 3% below its 52-week high and 57% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −40%, CRON screens richer than that median.

Fair Value models

Bear $2.15 Fair Value $2.16 Bull $2.16
Price $3.61 · Downside -40.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.1624 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $2.15 $2.16 $2.16 80
Growth DCF $2.15 $2.16 $2.16 78
5Y Revenue Exit $2.15 $2.16 $2.16 72
All 6 models by family
DCF Models
FCF DCF $2.15 $2.16 $2.16 80
5Y Revenue Exit $2.15 $2.16 $2.16 72
10Y Revenue Exit $2.15 $2.16 $2.16 66
Multiples
EV/Revenue $2.15 $2.15 $2.15 54
Asset-Based
NCAV (Graham) $1.51 $2.28 $2.85 55
Growth DCF
Growth DCF $2.15 $2.16 $2.16 78

Open the full fair value analysis →

Quality Score breakdown

Overall quality 59/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 8
How much profit the company makes from its sales and capital
Quality Growth 74
Are margins and returns getting better?
Cashflow 27
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 71
Does it invest with discipline instead of growing at any price?
Low Volatility 44
How calm the share price moves, does not count
Price momentum 79
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 89
Distance to the 52-week high, does not count
New shares 80
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 71/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+26.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.1%
Start year 2020 (pandemic). Over 10 years: +45.9% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+45.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−469.6% (2020) → −12.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CRON screens overvalued: fair value 40% below the price. Compare with Merck KGaA →

Compare Cronos Group Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 59 · Above median
Fair Value upside −40.2% · Below median
Profitability
Return on equity (12 months) 7.1% · Below median
Return on assets −0.8% · Bottom 25%
Net margin (12 months) 39.1% · Top 25%
Operating margin (12 months) 15.4% · Above median
Growth and dividend
Revenue growth (quarter YoY) 58.4% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 19.0× · Cheaper than median
P/B 1.27× · Cheaper than median
P/S (12 months) 7.77× · Priciest 25%
EV/EBITDA 50.4× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)28 · sector 29
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $111.63 +41% vs CRON
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs CRON
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs CRON
Haleon plc HLN $9.14 $8.61 −6% vs CRON
Merck KGaA MRK €148.75 €109.18 −27% vs CRON
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs CRON
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs CRON
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs CRON
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs CRON
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs CRON

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cronos Group Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cronos Group Inc Fair Value". https://www.fairvalue-calculator.com/stock/CRON

Frequently asked questions

Is Cronos Group Inc (CRON) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $2.16 versus a price of $3.61, about 40% lower (overvalued).
What is the fair value of CRON?
Our model-based fair value for Cronos Group Inc is $2.16 (as of Nov 6, 2026), built from audited fundamentals. The current price: $3.61.
What is the quality score of CRON?
Cronos Group Inc has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cronos Group Inc (CRON)?
Our model-based price target is the fair value of $2.16 (as of Nov 6, 2026) from 6 valuation models. Cautious scenario $2.15, optimistic scenario $2.16. It is a calculation from audited fundamentals, not an analyst target.
What is the Cronos Group Inc stock forecast for 2026?
Our models put fair value at $2.16, about 40% lower versus a price of $3.61 (overvalued). Cautious scenario $2.15, optimistic scenario $2.16. The calculation is refreshed regularly with new filings.
What is the revenue of Cronos Group Inc (CRON)?
Cronos Group Inc reported trailing-twelve-month revenue of about $179M (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Cronos Group Inc (CRON)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cronos Group Inc it is $2.16 per share (as of Nov 6, 2026), against a price of $3.61. It is the blended result of 6 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Cronos Group Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, CRON trades above its calculated fair value: price $3.61, fair value $2.16, a gap of about −40% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRON?
No. The price is what the market pays today ($3.61); the fair value is what the company's own numbers justify ($2.16). For Cronos Group Inc the two are $1.45 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cronos Group Inc worth?
The market values Cronos Group Inc at about $1.4B (market capitalisation, as of Nov 6, 2026). Per share that is $3.61; our models calculate a fair value of $2.16 per share.
What do the bullish and bearish scenarios say about CRON?
Our models span a range for Cronos Group Inc: cautious scenario $2.15, base $2.16, optimistic $2.16 per share (as of Nov 6, 2026, price $3.61). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CRON?
Cronos Group Inc trades at a price-to-earnings ratio of 19.0 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $2.16 is built from several models across several years. Other multiples: P/B 1.3, P/S 7.8, EV/EBITDA 50.4.
How solid is the balance sheet of Cronos Group Inc (CRON)?
Balance-sheet figures for Cronos Group Inc (as of Nov 6, 2026): return on equity 7.1%. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is CRON from its 52-week high?
Cronos Group Inc trades at $3.61, about 3% below its 52-week high of $3.72 and 57% above the low of $2.30 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $2.16 is for.
Which stocks are comparable to Cronos Group Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cronos Group Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $3.61, calculated fair value $2.16 (−40%), Quality Score 59/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CRON calculated?
We run Cronos Group Inc through 6 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of $2.16 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Cronos Group Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cronos Group Inc (CRON)?
The closing price on Nov 6, 2026 was $3.61. Our model-based fair value is $2.16, about 40% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cronos Group Inc right now?
The price sits above even our optimistic bull case ($2.16). The favourable scenario is already priced in. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band ($2.15 to $2.16), unusually little disagreement for a valuation.

Key figures of Cronos Group Inc

How large is the market capitalisation of Cronos Group Inc (CRON)?
The market capitalisation of Cronos Group Inc is $1.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cronos Group Inc (CRON)?
The price-to-sales ratio of Cronos Group Inc is 7.77 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cronos Group Inc (CRON)?
Earnings per share at Cronos Group Inc are $0.1900 (price ÷ EPS = P/E 19.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cronos Group Inc (CRON)?
The net margin of Cronos Group Inc is 39.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cronos Group Inc (CRON)?
The return on equity (ROE) of Cronos Group Inc is 7.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cronos Group Inc (CRON)?
On an EBIT basis the return on assets of Cronos Group Inc is −9.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cronos Group Inc (CRON)?
The operating margin of Cronos Group Inc is 15.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cronos Group Inc (CRON)?
Revenue at Cronos Group Inc is growing +58.4% versus a year earlier (3y avg +19.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cronos Group Inc (CRON)?
Earnings per share at Cronos Group Inc are growing +127% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Cronos Group Inc (CRON) generate?
The free cash flow of Cronos Group Inc is $152K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Cronos Group Inc (CRON) hold?
Cronos Group Inc holds more cash than debt, $790M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Cronos Group Inc in the live analysis

One click puts Cronos Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.